Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study

Documenti analoghi

• Dupilumab in Children Under 6 Years With Moderate‐to‐Severe Atopic Dermatitis: A 16‐Week Real‐World Prospective Study on Efficacy, Safety, and Local‐Systemic Immune Responses
  di: Yunxuan Zhang, et al.
  Pubblicazione: (2025)
• Real‐World Efficacy and Safety of Dupilumab Retreatment in Adults With Relapsed Atopic Dermatitis: A Retrospective Study From China
  di: Anda Zhang, et al.
  Pubblicazione: (2025)
• Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders
  di: Mutong Zhao, et al.
  Pubblicazione: (2024)
• Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis
  di: Yunha Kim, et al.
  Pubblicazione: (2025)
• Propionate alleviates itch in murine models of atopic dermatitis by modulating sensory TRP channels of dorsal root ganglion
  di: Yao Xu, et al.
  Pubblicazione: (2024)